1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Baker Bros. Advisors Lp Buys Madrigal Pharmaceuticals Inc, Allakos Inc, Tricida Inc, Sells Exact Sciences Corp, Audentes Therapeutics Inc, uniQure NV

New York, NY, based Investment company Baker Bros. Advisors Lp (Current Portfolio) buys Madrigal Pharmaceuticals Inc, Allakos Inc, Tricida Inc, Cerus Corp, Apellis Pharmaceuticals Inc, sells Exact Sciences Corp, Audentes Therapeutics Inc, uniQure NV, Adaptive Biotechnologies Corp, NextCure Inc during the 3-months ended 2020Q1, according to the most recent filings of the investment company, Baker Bros. Advisors Lp. As of 2020Q1, Baker Bros. Advisors Lp owns 101 stocks with a total value of $15.9 billion. These are the details of the buys and sells.

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

These are the top 5 holdings of BAKER BROS. ADVISORS LP
  1. Seattle Genetics Inc (SGEN) - 50,060,240 shares, 36.31% of the total portfolio. Shares added by 0.01%
  2. Incyte Corp (INCY) - 31,978,785 shares, 14.72% of the total portfolio. Shares added by 0.01%
  3. ACADIA Pharmaceuticals Inc (ACAD) - 41,904,586 shares, 11.13% of the total portfolio. Shares added by 2.57%
  4. BeiGene Ltd (BGNE) - 11,777,285 shares, 9.12% of the total portfolio.
  5. Alexion Pharmaceuticals Inc (ALXN) - 8,760,794 shares, 4.95% of the total portfolio. Shares added by 6.09%
New Purchase: Adaptimmune Therapeutics PLC (ADAP)

Baker Bros. Advisors Lp initiated holding in Adaptimmune Therapeutics PLC. The purchase prices were between $1.2 and $4.52, with an estimated average price of $3.32. The stock is now traded at around $4.86. The impact to a portfolio due to this purchase was 0.06%. The holding were 3,690,307 shares as of .

New Purchase: BioDelivery Sciences International Inc (BDSI)

Baker Bros. Advisors Lp initiated holding in BioDelivery Sciences International Inc. The purchase prices were between $3.06 and $6.32, with an estimated average price of $4.96. The stock is now traded at around $4.79. The impact to a portfolio due to this purchase was 0.04%. The holding were 1,638,334 shares as of .

New Purchase: Alector Inc (ALEC)

Baker Bros. Advisors Lp initiated holding in Alector Inc. The purchase prices were between $16.25 and $35.28, with an estimated average price of $25.37. The stock is now traded at around $31.47. The impact to a portfolio due to this purchase was 0.04%. The holding were 280,000 shares as of .

New Purchase: Horizon Therapeutics PLC (HZNP)

Baker Bros. Advisors Lp initiated holding in Horizon Therapeutics PLC. The purchase prices were between $24.87 and $38.56, with an estimated average price of $33.97. The stock is now traded at around $48.75. The impact to a portfolio due to this purchase was 0.04%. The holding were 200,000 shares as of .

New Purchase: Minerva Neurosciences Inc (NERV)

Baker Bros. Advisors Lp initiated holding in Minerva Neurosciences Inc. The purchase prices were between $4.57 and $9.23, with an estimated average price of $7.57. The stock is now traded at around $13.47. The impact to a portfolio due to this purchase was 0.03%. The holding were 688,531 shares as of .

New Purchase: Immunomedics Inc (IMMU)

Baker Bros. Advisors Lp initiated holding in Immunomedics Inc. The purchase prices were between $9.48 and $21.16, with an estimated average price of $16.95. The stock is now traded at around $33.30. The impact to a portfolio due to this purchase was 0.03%. The holding were 310,000 shares as of .

Added: Madrigal Pharmaceuticals Inc (MDGL)

Baker Bros. Advisors Lp added to a holding in Madrigal Pharmaceuticals Inc by 28.22%. The purchase prices were between $66.76 and $93.49, with an estimated average price of $83.57. The stock is now traded at around $116.42. The impact to a portfolio due to this purchase was 0.14%. The holding were 1,499,212 shares as of .

Added: Allakos Inc (ALLK)

Baker Bros. Advisors Lp added to a holding in Allakos Inc by 116.51%. The purchase prices were between $44.49 and $95.36, with an estimated average price of $68.99. The stock is now traded at around $69.42. The impact to a portfolio due to this purchase was 0.11%. The holding were 735,469 shares as of .

Added: Tricida Inc (TCDA)

Baker Bros. Advisors Lp added to a holding in Tricida Inc by 35.34%. The purchase prices were between $18.43 and $38.04, with an estimated average price of $32.3. The stock is now traded at around $27.19. The impact to a portfolio due to this purchase was 0.1%. The holding were 2,666,015 shares as of .

Added: Cerus Corp (CERS)

Baker Bros. Advisors Lp added to a holding in Cerus Corp by 27.57%. The purchase prices were between $2.87 and $5.49, with an estimated average price of $4.52. The stock is now traded at around $6.08. The impact to a portfolio due to this purchase was 0.09%. The holding were 13,713,195 shares as of .

Added: Apellis Pharmaceuticals Inc (APLS)

Baker Bros. Advisors Lp added to a holding in Apellis Pharmaceuticals Inc by 80.40%. The purchase prices were between $17.91 and $44.33, with an estimated average price of $35.6. The stock is now traded at around $34.06. The impact to a portfolio due to this purchase was 0.07%. The holding were 896,551 shares as of .

Added: Insmed Inc (INSM)

Baker Bros. Advisors Lp added to a holding in Insmed Inc by 23.72%. The purchase prices were between $13.63 and $33.98, with an estimated average price of $23.78. The stock is now traded at around $24.95. The impact to a portfolio due to this purchase was 0.06%. The holding were 3,025,384 shares as of .

Sold Out: Audentes Therapeutics Inc (BOLD)

Baker Bros. Advisors Lp sold out a holding in Audentes Therapeutics Inc. The sale prices were between $59.83 and $60, with an estimated average price of $59.94.

Sold Out: NextCure Inc (NXTC)

Baker Bros. Advisors Lp sold out a holding in NextCure Inc. The sale prices were between $32.32 and $58.37, with an estimated average price of $44.81.

Sold Out: Y-mAbs Therapeutics Inc (YMAB)

Baker Bros. Advisors Lp sold out a holding in Y-mAbs Therapeutics Inc. The sale prices were between $14.39 and $35.8, with an estimated average price of $29.19.

Sold Out: Marker Therapeutics Inc (GX1N)

Baker Bros. Advisors Lp sold out a holding in Marker Therapeutics Inc. The sale prices were between $1.48 and $2.93, with an estimated average price of $2.32.

Sold Out: Spring Bank Pharmaceuticals Inc (SBPH)

Baker Bros. Advisors Lp sold out a holding in Spring Bank Pharmaceuticals Inc. The sale prices were between $0.8 and $2.04, with an estimated average price of $1.3.

Sold Out: Trillium Therapeutics Inc (TRIL)

Baker Bros. Advisors Lp sold out a holding in Trillium Therapeutics Inc. The sale prices were between $1.03 and $7.22, with an estimated average price of $3.72.

Reduced: Exact Sciences Corp (EXAS)

Baker Bros. Advisors Lp reduced to a holding in Exact Sciences Corp by 28.6%. The sale prices were between $37.9 and $104.44, with an estimated average price of $81.73. The stock is now traded at around $83.89. The impact to a portfolio due to this sale was -0.37%. Baker Bros. Advisors Lp still held 1,846,139 shares as of .

Reduced: uniQure NV (QURE)

Baker Bros. Advisors Lp reduced to a holding in uniQure NV by 31.03%. The sale prices were between $40.01 and $73.97, with an estimated average price of $57.92. The stock is now traded at around $63.02. The impact to a portfolio due to this sale was -0.06%. Baker Bros. Advisors Lp still held 357,083 shares as of .

Reduced: Adaptive Biotechnologies Corp (ADPT)

Baker Bros. Advisors Lp reduced to a holding in Adaptive Biotechnologies Corp by 33.32%. The sale prices were between $16.96 and $34.16, with an estimated average price of $27.98. The stock is now traded at around $38.92. The impact to a portfolio due to this sale was -0.06%. Baker Bros. Advisors Lp still held 743,734 shares as of .

Reduced: Abeona Therapeutics Inc (ABEO)

Baker Bros. Advisors Lp reduced to a holding in Abeona Therapeutics Inc by 30.48%. The sale prices were between $1.45 and $4.08, with an estimated average price of $2.69. The stock is now traded at around $3.24. The impact to a portfolio due to this sale was -0.01%. Baker Bros. Advisors Lp still held 1,590,686 shares as of .

Reduced: Catalyst Pharmaceuticals Inc (CPRX)

Baker Bros. Advisors Lp reduced to a holding in Catalyst Pharmaceuticals Inc by 20.95%. The sale prices were between $2.61 and $5.21, with an estimated average price of $4.11. The stock is now traded at around $4.31. The impact to a portfolio due to this sale was -0.01%. Baker Bros. Advisors Lp still held 1,060,714 shares as of .

Reduced: G1 Therapeutics Inc (GTHX)

Baker Bros. Advisors Lp reduced to a holding in G1 Therapeutics Inc by 30.82%. The sale prices were between $9.07 and $26.43, with an estimated average price of $18.9. The stock is now traded at around $18.13. The impact to a portfolio due to this sale was -0.01%. Baker Bros. Advisors Lp still held 88,026 shares as of .



Here is the complete portfolio of BAKER BROS. ADVISORS LP. Also check out:

1. BAKER BROS. ADVISORS LP's Undervalued Stocks
2. BAKER BROS. ADVISORS LP's Top Growth Companies, and
3. BAKER BROS. ADVISORS LP's High Yield stocks
4. Stocks that BAKER BROS. ADVISORS LP keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)